Peyronie's disease is an under-diagnosed condition with prevalence in the male population as high as 9%. It is a localized connective tissue disorder of the penis characterized by scarring of the tunica albuginea. Its pathophysiology, however, remains incompletely elucidated.

For the management of the acute phase of Peyronie's disease, there are currently numerous available oral drugs, but the scientific evidence for their use is weak.

In terms of intralesional injections, Collagenase clostridium histolyticum is currently the only Food and Drug Administration-approved drug for the management of patients with Peyronie's disease and a palpable plaque with dorsal or dorsolateral curvature more than 30°.

Other available intralesional injectable drugs include Verapamil and Interferon-alpha-2b, however, their use is considered off-label.

Iontophoresis, shockwave therapy, and radiation therapy have also been described with unconvincing results, and as such, their use is currently not recommended.

Traction therapy, as part of a multimodal approach, is an underused additional tool for the prevention of Peyronie's disease-associated loss of penile length, but its efficacy is dependent on patient compliance.

Surgical therapy remains the gold standard for patients in the chronic phase of the disease.
In patients with adequate erectile function, tunical plication and/or incision/partial excision and grafting can be offered, depending on degree of curvature and/or presence of destabilizing deformity.
In patients with erectile dysfunction non-responsive to oral therapy, insertion of an inflatable penile prosthesis with or without straightening procedures should be offered. ( Xagena )

Yafi FA et al, Andrology 2015; 3: 650-660

XagenaMedicine2015